Loading data for ALNY — first visit, this takes a few seconds.

Alnylam Pharmaceuticals, Inc.

NasdaqGS: ALNY · Real-Time Price · USD
260.10
-6.01 (-2.26%)
At close: Sep 08, 2026, 3:59 PM

The price, the headline numbers and the latest news, in one place.

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, Analysis & Data

-2.26% (1D)
Bid243.01
Market Cap34.8B
Revenue (ttm)4.8B
Net Income (ttm)775M
0.30
5.75
45.23
20.86
P/B (ttm)25.69
P/S (ttm)7.24
Earnings DateOct 29, 2026
Ask235.64
Volume1,998,227
Avg. Volume (20D)1,813,230
Open259.73
Previous Close266.11
Day's Range254.00 - 272.08
52-Week Range197.81 - 495.55
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About ALNY

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxalu...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 1, 2004
Employees 2,500
Stock Exchange NasdaqGS
Ticker Symbol ALNY
Full Company Profile

Financial Performance

In 2025, Alnylam Pharmaceuticals's revenue was 3.71B, an increase of 65.19% compared to the previous year's 2.25B. Earnings were 313.75M, a decrease of -212.79%.

Financial Statements

Earnings Surprise

Alnylam Pharmaceuticals has released their quarterly earnings on Jul 30, 2026:
  • Revenue of $1.29B misses estimates by $0, with 66.86% YoY growth.
  • EPS of 1.84 misses estimates by -0.30, with 475.00% YoY growth.
Alnylam Pharmaceuticals, Inc. is scheduled to release its earnings on Oct 29, 2026, before market opens.
Analysts project revenue of ... Upgrade